These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 37143744)

  • 41. Clinical features of tuberculosis associated with HIV infection in Taiwan.
    Hsieh SM; Hung CC; Chen MY; Chang SC; Hsueh PR; Luh KT; Chuang CY
    J Formos Med Assoc; 1996 Dec; 95(12):923-8. PubMed ID: 9000809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gut microbiome contributes to impairment of immunity in pulmonary tuberculosis patients by alteration of butyrate and propionate producers.
    Maji A; Misra R; Dhakan DB; Gupta V; Mahato NK; Saxena R; Mittal P; Thukral N; Sharma E; Singh A; Virmani R; Gaur M; Singh H; Hasija Y; Arora G; Agrawal A; Chaudhry A; Khurana JP; Sharma VK; Lal R; Singh Y
    Environ Microbiol; 2018 Jan; 20(1):402-419. PubMed ID: 29322681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Microbiota of Human Lung of Pulmonary Tuberculosis and the Alteration Caused by Anti-tuberculosis Drugs.
    Zhang M; Shen L; Zhou X; Chen H
    Curr Microbiol; 2022 Sep; 79(11):321. PubMed ID: 36121489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of antibody responses against Mycobacterium tuberculosis antigen Rv0679c in tuberculosis patients from the endemic and non-endemic regions of the Beijing genotype: a case control study.
    Zhao J; Matsuba T; Zhang X; Leano S; Nakajima C; Chagan-Yasutan H; Telan EF; Suzuki Y; Hattori T
    BMC Infect Dis; 2017 May; 17(1):344. PubMed ID: 28506215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Bufei Jianpi Formula Improves Mucosal Immune Function by Remodeling Gut Microbiota Through the SCFAs/GPR43/NLRP3 Pathway in Chronic Obstructive Pulmonary Disease Rats.
    Mao J; Li Y; Bian Q; Xuan Y; Li J; Wang Z; Feng S; Liu X; Tian Y; Li S
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1285-1298. PubMed ID: 35673595
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intestinal microbiota disruption limits the isoniazid mediated clearance of Mycobacterium tuberculosis in mice.
    Negi S; Pahari S; Bashir H; Agrewala JN
    Eur J Immunol; 2020 Dec; 50(12):1976-1987. PubMed ID: 32673409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidemiological profile of tuberculosis in Iraq during 2011-2018.
    Ali ZA; Al-Obaidi MJ; Sameer FO; Mankhi AA; Misha'al KI; Jassim IA; Taqi EA; Ad'hiah AH
    Indian J Tuberc; 2022 Jan; 69(1):27-34. PubMed ID: 35074147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterizing the Composition of the Pediatric Gut Microbiome: A Systematic Review.
    Deering KE; Devine A; O'Sullivan TA; Lo J; Boyce MC; Christophersen CT
    Nutrients; 2019 Dec; 12(1):. PubMed ID: 31861722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence and speciation of non-tuberculous mycobacteria among pulmonary and extrapulmonary tuberculosis suspects in South India.
    Thangavelu K; Krishnakumariamma K; Pallam G; Dharm Prakash D; Chandrashekar L; Kalaiarasan E; Das S; Muthuraj M; Joseph NM
    J Infect Public Health; 2021 Mar; 14(3):320-323. PubMed ID: 33618276
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The lung microbiome in HIV-positive patients with active pulmonary tuberculosis.
    Ueckermann V; Lebre P; Geldenhuys J; Hoosien E; Cowan D; van Rensburg LJ; Ehlers M
    Sci Rep; 2022 May; 12(1):8975. PubMed ID: 35643931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alternation of Gut Microbiota in Patients with Pulmonary Tuberculosis.
    Luo M; Liu Y; Wu P; Luo DX; Sun Q; Zheng H; Hu R; Pandol SJ; Li QF; Han YP; Zeng Y
    Front Physiol; 2017; 8():822. PubMed ID: 29204120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome?
    Kapoor B; Gulati M; Gupta R; Singla RK
    Autoimmun Rev; 2023 May; 22(5):103313. PubMed ID: 36918089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between circulating levels of IFN-gamma, IL-10, CXCL9 and CCL2 in pulmonary and extrapulmonary tuberculosis is dependent on disease severity.
    Hasan Z; Jamil B; Khan J; Ali R; Khan MA; Nasir N; Yusuf MS; Jamil S; Irfan M; Hussain R
    Scand J Immunol; 2009 Mar; 69(3):259-67. PubMed ID: 19281538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The microbiome and the gut-lung axis in tuberculosis: interplay in the course of disease and treatment.
    Alvarado-Peña N; Galeana-Cadena D; Gómez-García IA; Mainero XS; Silva-Herzog E
    Front Microbiol; 2023; 14():1237998. PubMed ID: 38029121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study.
    Vinhaes CL; Oliveira-de-Souza D; Silveira-Mattos PS; Nogueira B; Shi R; Wei W; Yuan X; Zhang G; Cai Y; Barry CE; Via LE; Fukutani KF; Andrade BB; Mayer-Barber KD
    Cytokine; 2019 Nov; 123():154759. PubMed ID: 31226436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Excess fermentation and lactic acidosis as detrimental functions of the gut microbes in treatment-naive TB patients.
    Yunusbaeva M; Borodina L; Terentyeva D; Bogdanova A; Zakirova A; Bulatov S; Altinbaev R; Bilalov F; Yunusbayev B
    Front Cell Infect Microbiol; 2024; 14():1331521. PubMed ID: 38440790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A comparative study on the difference of gut microbiota and its biomarkers between patients with pulmonary tuberculosis and healthy controls].
    Lu YH; Shi WP; Hu Y; Xia F; Ning Z; Wu MY; Chen C; O Hu Y; Xu B
    Zhonghua Jie He He Hu Xi Za Zhi; 2021 Nov; 44(11):939-946. PubMed ID: 34758519
    [No Abstract]   [Full Text] [Related]  

  • 60. The Microbiota-Gut-Brain Axis in Alzheimer's Disease: A Review of Taxonomic Alterations and Potential Avenues for Interventions.
    Murray ER; Kemp M; Nguyen TT
    Arch Clin Neuropsychol; 2022 Feb; 37(3):595-607. PubMed ID: 35202456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.